Indeed, in the recent phase 3 CAPItello-291 study, combination of capivasertib and fulvestrant doubled PFS compared to fulvestrant singly in HR + , HER2- breast cancer patients who have developed resistance to aromatase inhibitors and CDK4/CDK6 inhibitors [285, 286]. This evidence concerns the gene ERBB2 and breast carcinoma.